Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
35
CARA Quote, Financials, Valuation and Earnings
Last price:
$0.42
Seasonality move
:
-5.48%
Day range:
$0.34 - $0.46
52-week range:
$0.23 - $1.15
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.66x
P/B ratio:
32.79x
Volume:
5.3M
Avg. volume:
2.4M
1-year change:
-30.34%
Market cap:
$23.2M
Revenue:
$21M
EPS (TTM):
-$1.75
Analysts' Opinion
-
Consensus RatingCara Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.01, Cara Therapeutics has an estimated upside of 139% from its current price of $0.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.42.
Fair Value
-
According to the consensus of 2 analysts, Cara Therapeutics has 139% upside to fair value with a price target of $1.01 per share.
CARA vs. S&P 500
-
Over the past 5 trading days, Cara Therapeutics has overperformed the S&P 500 by 64.57% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cara Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cara Therapeutics revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Cara Therapeutics reported revenues of $2.6M.
Earnings Growth
-
Cara Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cara Therapeutics reported earnings per share of -$0.23.
Enterprise value:
-18.9M
EV / Invested capital:
-26.67x
Price / LTM sales:
2.66x
EV / EBIT:
--
EV / Revenue:
-2.17x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
0.24x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$7.5M
Return On Assets:
-104.95%
Net Income Margin (TTM):
-1099.76%
Return On Equity:
-258.41%
Return On Invested Capital:
-258.41%
Operating Margin:
-206.61%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $39.4M | $21.2M | $8.7M | $4.9M | $2.6M | |
| Gross Profit | $34.3M | $13.5M | $7.5M | $3.3M | $2.6M | |
| Operating Income | -$89.8M | -$120.2M | -$79.9M | -$28.9M | -$5.3M | |
| EBITDA | -$88.9M | -$115.2M | -$88.8M | -$28M | -$10.4M | |
| Diluted EPS | -$1.66 | -$2.15 | -$1.75 | -$0.52 | -$0.23 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $132.8M | $171.5M | $186.8M | $100.6M | $47.9M | |
| Total Assets | $147.1M | $225.1M | $213.5M | $115.3M | $51.3M | |
| Current Liabilities | $16.6M | $15.5M | $28.2M | $22.9M | $10M | |
| Total Liabilities | $19.3M | $17.9M | $28.7M | $29.7M | $50.6M | |
| Total Equity | $127.8M | $207.2M | $184.8M | $85.6M | $707K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$56.5M | -$98.2M | -$74.2M | -$19.6M | -$14M | |
| Cash From Investing | $30.7M | $118.1M | $13.5M | $23.2M | $2.5M | |
| Cash From Financing | $45.6M | $1.7M | $34.5M | $1.1M | -$694K | |
| Free Cash Flow | -$56.5M | -$98.5M | -$77.3M | -$20M | -$14M | |
CARA
Sector
Market Cap
$23.2M
$44.6M
Price % of 52-Week High
36.75%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-30.35%
-29.09%
Beta (5-Year)
0.641
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.30
200-day SMA
Sell
Level
$0.47
Bollinger Bands (100)
Buy
Level
0.26 - 0.34
Chaikin Money Flow
Sell
Level
-117.5M
20-day SMA
Buy
Level
$0.29
Relative Strength Index (RSI14)
Buy
Level
75.89
ADX Line
Buy
Level
13.78
Williams %R
Neutral
Level
-32.9816
50-day SMA
Buy
Level
$0.29
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
128M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.3262)
Sell
CA Score
(Annual)
Level (-2.9416)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.6094)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Stock Forecast FAQ
In the current month, CARA has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CARA average analyst price target in the past 3 months is $1.01.
-
Where Will Cara Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cara Therapeutics share price will rise to $1.01 per share over the next 12 months.
-
What Do Analysts Say About Cara Therapeutics?
Analysts are divided on their view about Cara Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cara Therapeutics is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Cara Therapeutics's Price Target?
The price target for Cara Therapeutics over the next 1-year time period is forecast to be $1.01 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CARA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cara Therapeutics is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CARA?
You can purchase shares of Cara Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cara Therapeutics shares.
-
What Is The Cara Therapeutics Share Price Today?
Cara Therapeutics was last trading at $0.42 per share. This represents the most recent stock quote for Cara Therapeutics. Yesterday, Cara Therapeutics closed at $0.42 per share.
-
How To Buy Cara Therapeutics Stock Online?
In order to purchase Cara Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
